{
  "id": "5880b2a6c872c95565000004",
  "type": "list",
  "question": "Signaling of which pathways is inhibited by Dupilumab?",
  "ideal_answer": "Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling. It is used for treatment of atopic or allergic diseases.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27130691",
    "http://www.ncbi.nlm.nih.gov/pubmed/25482871",
    "http://www.ncbi.nlm.nih.gov/pubmed/25006719",
    "http://www.ncbi.nlm.nih.gov/pubmed/26454361",
    "http://www.ncbi.nlm.nih.gov/pubmed/26598956",
    "http://www.ncbi.nlm.nih.gov/pubmed/27334730",
    "http://www.ncbi.nlm.nih.gov/pubmed/26440137",
    "http://www.ncbi.nlm.nih.gov/pubmed/27690741",
    "http://www.ncbi.nlm.nih.gov/pubmed/25214796",
    "http://www.ncbi.nlm.nih.gov/pubmed/25645542",
    "http://www.ncbi.nlm.nih.gov/pubmed/26308331",
    "http://www.ncbi.nlm.nih.gov/pubmed/27525671",
    "http://www.ncbi.nlm.nih.gov/pubmed/27637004",
    "http://www.ncbi.nlm.nih.gov/pubmed/25542094",
    "http://www.ncbi.nlm.nih.gov/pubmed/27497276",
    "http://www.ncbi.nlm.nih.gov/pubmed/26967382",
    "http://www.ncbi.nlm.nih.gov/pubmed/27223113",
    "http://www.ncbi.nlm.nih.gov/pubmed/26457448",
    "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
    "http://www.ncbi.nlm.nih.gov/pubmed/26836729",
    "http://www.ncbi.nlm.nih.gov/pubmed/23688323",
    "http://www.ncbi.nlm.nih.gov/pubmed/24275927"
  ],
  "snippets": [
    {
      "text": "This study reviewed all studies about any roles of IL-4 that can directly and indirectly be played in the development of pemphigus and IL-4 inhibition with interferons and dupilumab therapy were introduced as a novel pemphigus treatment for patients who are in relapse phase of the disease. Dupilumab was also introduced as a possible treatment for patients with severe pemphigus. It can directly inhibit IL-4 by targeting IL-4 \u03b1-chain receptor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440137",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836729",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-IL-4 and IL-13 agents (dupilumab, lebrikizumab, and tralokinumab) which block different Th-2 inflammatory pathways and agents targeting the Th-17 inflammatory pathway in severe refractory asthma are under development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27334730",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor \u03b1-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497276",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The world's first prospective controlled studies with the biologic human anti-IL4R antibody dupilumab for the indication \"atopic dermatitis\" were published in 2014.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645542",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An IL-4R antagonist, dupilumab, is the first drug that shows great promise in phase II trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25542094",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab, a humanized monoclonal antibody to the interteukin-4R is the first antibody (i.e. 'biological') with published efficacy shown in controlled prospective studies in atopic dermatitis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308331",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26454361",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor \ufffd, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature.METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo.RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor \u00e1, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature.METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo.RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482871",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://amigo.geneontology.org/amigo/term/GO:0023052",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015398"
  ],
  "exact_answer": "interleukin-4, interleukin-13"
}